FDA Approves Labeling Changes for GE Healthcare's Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
8/21/2012 9:58:57 AM
PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare today announced important changes to the U.S. product label for Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the visualization of the left ventricular border – an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy. Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve delineation of the left ventricular endocardial borders.
comments powered by